The global emergence of many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants jeopardizes the protective antiviral immunity induced after infection or …

The International AIDS Vaccine Initiative has established a consortium to elucidate mechanisms
of protection conferred by live attenuated simian immunodeficiency virus vaccines in …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations may diminish
vaccine-induced protective immune responses, particularly as antibody titers wane over time. …

In the coronavirus efficacy (COVE) phase 3 clinical trial, vaccine recipients were assessed
for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as …

Persistence of Antibody after mRNA-1273 Vaccination A total of 33 participants who received
both doses of the Moderna mRNA-1273 vaccine against SARS-CoV-2 had blood drawn …

Background Although the three vaccines against coronavirus disease 2019 (Covid-19) that
have received emergency use authorization in the United States are highly effective, …

Background Testing of vaccine candidates to prevent infection with severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) in an older population is important, since increased …

… cellular response to mRNA-1273 is not yet defined, this vaccine elicited primary CD4 type
1 helper T responses 43 days after the first vaccination, 2 and studies of vaccine-induced B …

INTRODUCTION Worldwide appearance of severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) variants of concern (VOCs) with increased transmissibility and resistance to …

The complex interplay between the host immune response and HIV has been the subject of
intense research over the last 25 years. HIV and simian immunodeficiency virus (SIV) CD8+ …